[EN] HYDROXYALKANYL AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY [FR] AMIDES D'HYDROXYALCANYLE EN TANT QUE MODULATEURS DE L'ACTIVITÉ DE RÉCEPTEUR DE CHIMIOKINE
[EN] HYDROXYALKANYL AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY [FR] AMIDES D'HYDROXYALCANYLE EN TANT QUE MODULATEURS DE L'ACTIVITÉ DE RÉCEPTEUR DE CHIMIOKINE
Hydroxyalkanyl amides as modulators of chemokine receptor activity
申请人:Carter Percy H.
公开号:US08492550B2
公开(公告)日:2013-07-23
The application describes modulators of MIP-1α or CCR-1 of the formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein ring A, T, V, R1, R2 and R5, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
HYDROXYALKANYL AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
申请人:Carter Percy H.
公开号:US20110009452A1
公开(公告)日:2011-01-13
The application describes modulators of MIP-1α or CCR-1 of the formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein ring A, T, V, R
1
, R
2
and R
5
, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
[EN] HYDROXYALKANYL AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] AMIDES D'HYDROXYALCANYLE EN TANT QUE MODULATEURS DE L'ACTIVITÉ DE RÉCEPTEUR DE CHIMIOKINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2009111607A1
公开(公告)日:2009-09-11
The application describes modulators of MIP-1α or CCR-1 of the formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein ring A, T, V, R1, R2 and R5, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.